IPO - Profile


We are a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the CNS. Our company was founded on the premise that the upper nasal cavity can be an optimal treatment entry point for CNS and other diseases where rapid vascular absorption can result in superior clinical outcomes. Our strategy is to pair our proprietary POD upper nasal delivery technology with well-established therapeutics or other therapeutics where More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$15.00 5,330,000 Positive High 56.21%

Offering Team

  • Legal counsel
  • Fenwick & West LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 22 Apr, 2021

Offer 23 Apr, 2021

Look Ahead

Lock Up Expiry Oct 23, 2021

IPO Terms

Offer Price $15.00
Offer Size 5M

Market Sentiments

Stock Price